| 供貨周期 |
一周 |
規(guī)格 |
T25 |
| 貨號(hào) |
CCRF |
應(yīng)用領(lǐng)域 |
醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
| 主要用途 |
科學(xué)研究 |
CCRF HSB-2細(xì)胞， 人急性淋巴母細(xì)胞型白血病細(xì)胞 CCRF HSB-2人急性淋巴母細(xì)胞型白血病細(xì)胞
原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，
提供參考文獻(xiàn)和*培養(yǎng)條件！
CCRF HSB-2細(xì)胞， 人急性淋巴母細(xì)胞型白血病細(xì)胞
| ATCC® Number: | CCL-120.1™ | Price: | $338.00 |
| Designations: | CCRF-HSB-2 [CCRF HSB-2, HSB-2] |
|
| | Depositors: | GE Foley |
|
| | Biosafety Level: | 1 |
|
| | Shipped: | frozen |
|
| | Medium & Serum: | See Propagation |
|
| | Growth Properties: | suspension |
|
| | Organism: | Homo sapiens (human) |
|
| | Morphology: | lymphoblast
|
|
| | Source: | Organ: peripheral blood
Disease: acute lymphoblastic leukemia
Cell Type: T lymphoblast; |
|
| | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | | CCRF HSB-2細(xì)胞， 人急性淋巴母細(xì)胞型白血病細(xì)胞 |
|
| | Tumorigenic: | Yes |
|
| | Antigen Expression: | HLA A1, A2, B12, B17, Cw2; CD5 (78%), CD7 (96%) |
|
| | DNA Profile (STR): | Amelogenin: X,Y CSF1PO: 10,12 D13S317: 10,12 D16S539: 9,13 D5S818: 11,12 D7S820: 11,12 THO1: 9,10 TPOX: 8 vWA: 18,19 |
|
| | Isoenzymes: | G6PD, B |
|
| | Age: | 11.5 years |
|
| | Gender: | male CCRF HSB-2細(xì)胞， 人急性淋巴母細(xì)胞型白血病細(xì)胞 |
|
| | Ethnicity: | Caucasian |
|
| | Comments: | Derived from the same buffy coat preparation as CCL-120 (CCRF-SB) by serially transplanting into newborn syrian hamsters. |
|
| | Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C |
|
| | Subculturing: | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 3 - 5 X 10 exp5 viable cells/ml. A maximum of 2 - 3 X 10 exp6 viable cells/ml is obtainable. |
|
| | Preservation: | culture medium 95%; DMSO, 5% |
|
| | Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005 recommended serum:ATCC 30-2020 derived from same individual:ATCC CCL-120 |
|
| | References: | 24413: . M.D. Anderson Hospital and Tumor Inst. Monograph. 21: ; 1967.
25969: Adams RA, et al. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2. Cancer Res. 28: 1121-1125, 1968. PubMed: 4872716
26035: . . Proc. Am. Assoc. Cancer Res. 8: 1, 1967. |
|
|
會(huì)員.png)
15
